Marwan Fakih - Researcher Profile | RDL Research Database

Publications

4 shown

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

2020 The Lancet Oncology 2300 citations

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon , Karen Rex , Anne Y. Saiki +31 more

2019 Nature 2068 citations

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele , Alexander Drilon , Luis Paz‐Ares +35 more

Ignyta/F Hoffmann-La Roche.

2019 The Lancet Oncology 1625 citations

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong , Marwan Fakih , John H. Strickler +31 more

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the <i>KRAS</i> p.G12C mutation. Grade 3 or 4 treatment-rela...

2020 New England Journal of Medicine 1570 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 7,563
Institution: City of Hope

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6554-5488

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.